1887
Editorial Open Access
Like 0
This item has no PDF Download

Abstract

BCG (Bacillus Calmette-Guerin) vaccine was developed from an attenuated strain of Mycobacterium bovis at the beginning of the twentieth century. Its widespread use as a vaccine against tuberculosis spread in Europe, and subsequently globally, over the next 50 years. It remains one of the most frequently administered vaccines in the world. It has also been one of the most controversial. Widely differing estimates of the effectiveness of BCG at protecting against different forms of tuberculosis in different population subgroups in different settings have been published [1]. Some countries, with a low incidence of tuberculosis, did not adopt the use of BCG vaccine at all and some others abandoned its use at a later stage. In addition, great variation developed in national programmes for the administration of BCG including the age(s) at which it should be given, whether or not its administration should be preceded by tuberculin sensitivity testing, and whether repeat vaccinations with BCG should be given.

Loading

Article metrics loading...

/content/10.2807/esm.11.03.00603-en
2006-03-01
2017-11-24
http://instance.metastore.ingenta.com/content/10.2807/esm.11.03.00603-en
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/11/3/art00603-en.htm?itemId=/content/10.2807/esm.11.03.00603-en&mimeType=html&fmt=ahah
Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error